TMEM165 and breast cancer: These results indicate that the changes that occur in TMEM165 in CDG patients that disrupt function are not disrupting the function of TMEM165 in the MDAMB231 breast cancer cells as these mutants were capable of inducing the glycoform of nicastrin observed in MDAMB231 control cells.